Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RDPTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radiopharm Theranostics Limited filings document foreign private issuer reports that furnish Australian Securities Exchange announcements to the SEC. The Form 6-K record covers quarterly activities and Appendix 4C cash-flow reports, along with clinical updates for the company's oncology radiopharmaceutical programs.
Disclosures address RAD 101 brain-metastasis imaging, 177Lu-RAD202 in HER2-positive solid tumors, radiotherapeutic assets RV-01 and RAD 402, trial data presentations, safety-monitoring committee recommendations, cash-flow reporting, and Exchange Act furnishing status for exhibits attached to its public notices.
Radiopharm Theranostics Ltd executive Dimitris Voliotis, the Chief Medical Officer, reported his initial holdings of stock options in a Form 3. These options give him the right to buy Ordinary Shares at an exercise price of $0.025 per share.
The filing shows three option positions over Ordinary Shares: one over 7,657,334 shares with an exercise date of July 1, 2028, and two over 7,657,333 shares each with exercise dates of July 1, 2027 and July 1, 2026. All three option positions are scheduled to expire on July 1, 2030 and are held directly. The filing does not report any purchases or sales, only these existing derivative holdings.
Radiopharm Theranostics Ltd executive Dimitris Voliotis, the Chief Medical Officer, reported his initial holdings of stock options in a Form 3. These options give him the right to buy Ordinary Shares at an exercise price of $0.025 per share.
The filing shows three option positions over Ordinary Shares: one over 7,657,334 shares with an exercise date of July 1, 2028, and two over 7,657,333 shares each with exercise dates of July 1, 2027 and July 1, 2026. All three option positions are scheduled to expire on July 1, 2030 and are held directly. The filing does not report any purchases or sales, only these existing derivative holdings.
Radiopharm Theranostics Ltd director Paul Hopper has filed an initial Form 3 listing his ownership in Ordinary Shares and options. The filing shows direct ownership of 53,900,000 Ordinary Shares, plus additional indirect holdings through Kilinwata Investments Pty Ltd and his spouse. It also details multiple Option (right to buy) positions over Ordinary Shares with exercise prices between 0.0250 and 0.2000 and expirations ranging from 2026 to 2030, including grants that vest only if he remains a Director on specified future dates.
Radiopharm Theranostics Ltd director Paul Hopper has filed an initial Form 3 listing his ownership in Ordinary Shares and options. The filing shows direct ownership of 53,900,000 Ordinary Shares, plus additional indirect holdings through Kilinwata Investments Pty Ltd and his spouse. It also details multiple Option (right to buy) positions over Ordinary Shares with exercise prices between 0.0250 and 0.2000 and expirations ranging from 2026 to 2030, including grants that vest only if he remains a Director on specified future dates.
Radiopharm Theranostics Ltd filed an initial Form 3 for Chief Financial Officer Aaron James Laurita, establishing his existing equity position. He directly holds 26,357 Ordinary Shares and an option to buy 17,857 Ordinary Shares at an exercise price of $0.2000 per share, expiring on November 30, 2026. The filing records holdings rather than new share purchases or sales.
Radiopharm Theranostics Ltd filed an initial Form 3 for Chief Financial Officer Aaron James Laurita, establishing his existing equity position. He directly holds 26,357 Ordinary Shares and an option to buy 17,857 Ordinary Shares at an exercise price of $0.2000 per share, expiring on November 30, 2026. The filing records holdings rather than new share purchases or sales.
Radiopharm Theranostics reported its quarterly cash flow and business update, highlighting rapid clinical progress alongside heavy spending. Closing cash at the end of the quarter was A$19.2 million, down from A$34.5 million, after net operating cash outflows of A$14.9 million.
Direct research and development of A$11.8 million plus staff costs of A$2.37 million made up 95% of operating spend, reflecting accelerated investment across its radiopharmaceutical pipeline. Key milestones included completing enrolment in the Phase 2b trial of imaging agent RAD 101, where interim data showed 90% concordance with MRI in 18 of 20 evaluable subjects, and advancing RAD 202 with encouraging early safety and tumor uptake data.
The company also initiated first-in-human trials for radiotherapeutic assets RV-01 and RAD 402 and continues multiple Phase 1 programs. Estimated funding runway is 1.29 quarters, but management points to an A$-equivalent At-The-Market facility allowing up to US$18.9 million in ADR issuance and an expected ~A$5 million Australian R&D tax incentive to extend liquidity.
Radiopharm Theranostics reported its quarterly cash flow and business update, highlighting rapid clinical progress alongside heavy spending. Closing cash at the end of the quarter was A$19.2 million, down from A$34.5 million, after net operating cash outflows of A$14.9 million.
Direct research and development of A$11.8 million plus staff costs of A$2.37 million made up 95% of operating spend, reflecting accelerated investment across its radiopharmaceutical pipeline. Key milestones included completing enrolment in the Phase 2b trial of imaging agent RAD 101, where interim data showed 90% concordance with MRI in 18 of 20 evaluable subjects, and advancing RAD 202 with encouraging early safety and tumor uptake data.
The company also initiated first-in-human trials for radiotherapeutic assets RV-01 and RAD 402 and continues multiple Phase 1 programs. Estimated funding runway is 1.29 quarters, but management points to an A$-equivalent At-The-Market facility allowing up to US$18.9 million in ADR issuance and an expected ~A$5 million Australian R&D tax incentive to extend liquidity.
Radiopharm Theranostics Limited reported initial first-in-human findings from its Phase 0/1 HEAT clinical trial of 177Lu-RAD202, a HER2-targeted radiopharmaceutical for advanced solid tumors. In the initial lowest dose cohort of three heavily pre-treated HER2-positive patients given 30 mCi, 177Lu-RAD202 showed encouraging tumor uptake and a favorable safety profile. Based on these data, the independent Data Safety and Monitoring Committee recently recommended advancing to the next dose level, allowing escalation to the third cohort at 130 mCi. The HEAT trial is an open-label, multicenter study in HER2-positive locally-advanced or metastatic solid tumors, building on earlier diagnostic proof-of-concept for RAD202 in HER2-positive breast cancer.
Radiopharm Theranostics Limited reported initial first-in-human findings from its Phase 0/1 HEAT clinical trial of 177Lu-RAD202, a HER2-targeted radiopharmaceutical for advanced solid tumors. In the initial lowest dose cohort of three heavily pre-treated HER2-positive patients given 30 mCi, 177Lu-RAD202 showed encouraging tumor uptake and a favorable safety profile. Based on these data, the independent Data Safety and Monitoring Committee recently recommended advancing to the next dose level, allowing escalation to the third cohort at 130 mCi. The HEAT trial is an open-label, multicenter study in HER2-positive locally-advanced or metastatic solid tumors, building on earlier diagnostic proof-of-concept for RAD202 in HER2-positive breast cancer.
Radiopharm Theranostics completed enrollment in its U.S. Phase 2b imaging trial of RAD 101 for diagnosing recurrent brain metastases from solid tumors. Interim data showed 90% concordance between 18F‑RAD101 and MRI, which is the study’s primary endpoint. A primary endpoint readout is expected in June 2026, and the company plans to advance RAD 101 into a U.S. Phase 3 pivotal trial and engage with the FDA on the regulatory path. RAD 101 targets fatty acid synthase, which is overexpressed in many solid tumors, and has received FDA Fast Track Designation for distinguishing recurrent disease from treatment effects in brain metastases.
Radiopharm Theranostics completed enrollment in its U.S. Phase 2b imaging trial of RAD 101 for diagnosing recurrent brain metastases from solid tumors. Interim data showed 90% concordance between 18F‑RAD101 and MRI, which is the study’s primary endpoint. A primary endpoint readout is expected in June 2026, and the company plans to advance RAD 101 into a U.S. Phase 3 pivotal trial and engage with the FDA on the regulatory path. RAD 101 targets fatty acid synthase, which is overexpressed in many solid tumors, and has received FDA Fast Track Designation for distinguishing recurrent disease from treatment effects in brain metastases.
Radiopharm Theranostics reports that an independent Data Safety and Monitoring Committee has recommended advancing its Phase 1 ‘HEAT’ trial of radiotherapeutic candidate 177Lu-RAD202 to Cohort 3 at a dose of 130mCi in HER2-positive advanced solid tumors.
The decision follows favorable safety data that allowed faster progression from Cohort 2. A prior dose level of 75mCi was announced earlier, and the company states it remains on track to complete Phase 1 dose escalation by the end of 2026. RAD202 previously showed proof-of-concept and positive safety in a ten-patient HER2-positive breast cancer study.
Radiopharm Theranostics reports that an independent Data Safety and Monitoring Committee has recommended advancing its Phase 1 ‘HEAT’ trial of radiotherapeutic candidate 177Lu-RAD202 to Cohort 3 at a dose of 130mCi in HER2-positive advanced solid tumors.
The decision follows favorable safety data that allowed faster progression from Cohort 2. A prior dose level of 75mCi was announced earlier, and the company states it remains on track to complete Phase 1 dose escalation by the end of 2026. RAD202 previously showed proof-of-concept and positive safety in a ten-patient HER2-positive breast cancer study.
Radiopharm Theranostics Limited filed a Form 6-K to furnish an announcement that it has signed a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. Siemens will radiolabel and distribute 18F-labeled RAD101 to support a planned multi-center global Phase 3 registrational trial.
Interim data from a Phase 2b trial showed 90% concordance (18 of 20 patients) between RAD101 PET imaging and MRI, the study’s primary endpoint, with significant and selective tumor uptake in brain metastases. Early six-month follow-up in five evaluable patients indicates a positive trend for sensitivity and specificity. RAD101 has received U.S. FDA Fast Track Designation for distinguishing recurrent brain metastases from treatment effects, and topline Phase 2b data are expected in the first half of 2026.
Radiopharm Theranostics Limited filed a Form 6-K to furnish an announcement that it has signed a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. Siemens will radiolabel and distribute 18F-labeled RAD101 to support a planned multi-center global Phase 3 registrational trial.
Interim data from a Phase 2b trial showed 90% concordance (18 of 20 patients) between RAD101 PET imaging and MRI, the study’s primary endpoint, with significant and selective tumor uptake in brain metastases. Early six-month follow-up in five evaluable patients indicates a positive trend for sensitivity and specificity. RAD101 has received U.S. FDA Fast Track Designation for distinguishing recurrent brain metastases from treatment effects, and topline Phase 2b data are expected in the first half of 2026.
Radiopharm Theranostics Ltd director Ian Lawrence Turner has filed an initial Form 3 detailing his equity position in RADX. The filing shows direct ownership of 6,985,292 Ordinary Shares and indirect ownership of 3,000,000 Ordinary Shares held through the Turner Discretionary Trust, where he is the sole beneficiary.
Mr. Turner also holds multiple option awards over Ordinary Shares with exercise prices ranging from 0.0250 to 0.2000 per share and expirations between 2026 and 2030. Footnotes explain that several grants vest in tranches between July 2026 and July 2028, in some cases only if he remains a director or achieves specified milestones.
Radiopharm Theranostics Ltd director Ian Lawrence Turner has filed an initial Form 3 detailing his equity position in RADX. The filing shows direct ownership of 6,985,292 Ordinary Shares and indirect ownership of 3,000,000 Ordinary Shares held through the Turner Discretionary Trust, where he is the sole beneficiary.
Mr. Turner also holds multiple option awards over Ordinary Shares with exercise prices ranging from 0.0250 to 0.2000 per share and expirations between 2026 and 2030. Footnotes explain that several grants vest in tranches between July 2026 and July 2028, in some cases only if he remains a director or achieves specified milestones.
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position. The filing shows direct ownership of 22,679,986 Ordinary Shares, along with multiple option awards over additional Ordinary Shares at exercise prices ranging from $0.025 to $0.60 per share and expirations between 2026 and 2030.
Footnotes state that significant blocks of options granted in 2023, 2024 and 2025 will vest in stages on July 1 of 2026, 2027 and 2028, provided Mr. Canevari remains a Director on those dates.
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position. The filing shows direct ownership of 22,679,986 Ordinary Shares, along with multiple option awards over additional Ordinary Shares at exercise prices ranging from $0.025 to $0.60 per share and expirations between 2026 and 2030.
Footnotes state that significant blocks of options granted in 2023, 2024 and 2025 will vest in stages on July 1 of 2026, 2027 and 2028, provided Mr. Canevari remains a Director on those dates.